mTOR signalling in serous ovarian cancer

浆液性卵巢癌是澳大利亚妇女中最具侵袭性和致命性的妇科癌症。 哺乳动物雷帕霉素靶蛋白（mTOR）的激活经常被观察到，并与卵巢癌患者的预后不良相关。然而，在卵巢癌的发病机制中mTOR失调的机制尚不清楚。在初步研究中，在高达60%的人类浆液性卵巢癌患者中观察到调节mTOR信号传导的基因缺失。该项目将提供mTOR信号通路参与浆液性卵巢癌发病机制的详细信息，并为这些患者靶向mTOR通路提供理论依据。

Serous ovarian cancer is the most aggressive and lethal gynaecological cancer in Australian women. Activation of Mammalian Target of Rapamycin (mTOR) is frequently observed and associated with poor prognosis in ovarian cancer patients. However, the mechanisms dysregulating mTOR in the pathogenesis of ovarian cancer are unknown. In preliminary studies, deletion of genes regulating mTOR signalling in up to 60 per cent of human serous ovarian cancer patients was observed. This project will provide mechanistic details of involvement of mTOR signalling in pathogenesis of the serous ovarian carcinoma, and develop a rationale for targeting mTOR pathway in these patients.